At Capsigen, we’re developing the next generation of Adeno Associated Viral vectors to fuel the gene therapy needs of the future.  Our end-to-end platform employs highly diverse libraries and screens using the most clinically relevant models and routes of administration.  Our proprietary TRADE™ technology eliminates background and employs novel selection strategies to identify only those vectors which are fully functional to meet the disease-specific transduction criteria of interest.  The platform incorporates advanced data science technologies to add detargeting and immune evasion phenotypes.  The final results are dose optimized, fit-for-purpose vectors designed to deliver the highest level of clinical utility in a rapid and high-throughput manner.

Company Details